Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy diversity 3-3 (IGHD3-3) is one of approximately 25 functional diversity (D) gene segments within the immunoglobulin heavy chain (IGH) locus on chromosome 14[5][3]. During B cell development, a single D gene segment, such as IGHD3-3, recombines with specific variable (V) and joining (J) gene segments through the V(D)J recombination process. This generates the variable domain of immunoglobulin heavy chains essential for antigen specificity in antibodies[2]. The IGHD3-3 segment itself does not encode a full protein; rather, it contributes to the hypervariable region of the antibody, impacting antigen recognition and overall immune diversity[3][2]. IGHD3-3 is not considered a direct therapeutic target or receptor but is integral for immune repertoire diversity, and germline or somatic variation in this locus has been associated with differential immune responses in health and disease[4]. No drugs, drug mechanisms, or established biomarker roles are directly associated with IGHD3-3.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy diversity 3-3 (IGHD3-3).